Drugs / Vevorisertib
last change Mar 2023 re-read 2 minutes ago

Vevorisertib

Small molecule

Developed for
cancer
Investigated by
ArQule, Inc.

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02761694 Jun 2016 → Mar 2021 cancer ArQule, Inc. Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Vevorisertib ClinicalTrials.gov intervention name — accepted as the source's own label NCT02761694
Action Inhibit “pan-AKT inhibitor” PMID 36970876 Mar 2023
Modality Small molecule CHEMBL4802156